Compare KeyCorp (KEY) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KeyCorp vs Novartis AG — how do they compare? KeyCorp trades at $20.01 (market cap $21.45B), while Novartis AG trades at $143.74 (market cap $268.57B). The key difference: Novartis AG is far larger — about 12.5× KeyCorp's market cap, and KeyCorp pays the higher dividend (4.08%). Which is the better fit depends on your goals — on Pluang, investors hold KeyCorp for 66 Days and Novartis AG for 82 Days on average.
| KEY | NVS | |
|---|---|---|
Market Cap | $21.45B | $268.57B |
Volume | 19,450,846 | 1,532,573 |
Sector | Financials | Health |
52-Week High | $23.99 | $168.62 |
52-Week Low | $16.78 | $121.80 |
Typical Hold Time | 66 Days | 82 Days |
Enterprise Value | $34.63B | $309.89B |
Dividend Yield | 4.08% | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KeyCorp (KEY) trades at $19.985, up 0.78% on the day, with strong fundamental metrics including a P/E of 11.75 and net income margin of 26.72%. The stock shows consistent earnings beats in recent quarters and maintains a solid dividend yield. Technical indicators suggest bearish momentum despite neutral oscillators, while analyst consensus remains strongly bullish with a $25.00 price target representing 25% upside potential from current levels.
KEY presents a compelling value opportunity with attractive valuation multiples and strong profitability, though technical weakness and frozen dividend payments pose near-term concerns. The bank's improved revenue guidance for 2026 and aggressive share buyback program support EPS growth, while interest rate sensitivity remains a key risk factor for the regional banking sector.
Novartis (NVS) trades at $143.22, down 0.04% on the day, near the analyst consensus price target of $146. The stock shows mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company reported strong 2025 revenue of $56.67B and net income of $13.98B, with a robust net margin of 24.67%. Recent developments include a significant $7.8B licensing deal with China's Abogen for mRNA therapy, though this follows clinical setbacks in other drug programs.
The outlook is cautiously optimistic. The Abogen deal expands the pipeline in autoimmune diseases, a growth area, and analyst consensus leans Hold with a slight upside to the price target. Key risks include integration challenges from recent acquisitions, pipeline volatility after trial failures, and investor scrutiny over M&A strategy. Earnings momentum is mixed, with a recent beat in Q2 but a miss in Q1, requiring consistent execution to justify current valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About KeyCorp
With assets of over $170 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
Read more on KEY →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
